Drug Type Small molecule drug |
Synonyms N9-DNJ, UV 4, UV 4B + [1] |
Target |
Action inhibitors |
Mechanism α-glucosidase inhibitors(Acidic alpha-glucosidase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC16H33NO5 |
InChIKeyTYTARGBBJQKLAJ-QKPAOTATSA-N |
CAS Registry615253-61-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Virus Diseases | Phase 1 | United States | 01 Jul 2014 | |
Dengue | Phase 1 | United States | - | |
Influenza, Human | Preclinical | United States | - |
NCT02061358 (Pubmed) Manual | Phase 1 | - | 64 | kqdviwyqmf(tqatwlgvrq) = there were no serious adverse events reported . rxqjtxkcmo (gcktenjgnu ) View more | Positive | 08 Aug 2022 | |
Placebo | |||||||
Phase 1 | 7 | (Cohort 1 - 30 mg UV-4B) | rerpplopdd = qrxttmhxql ohbfdvpehl (qtnzuckqra, tkftljlneo - djjhvmmqxo) View more | - | 16 Mar 2018 | ||
placebo (Cohort 1 - Placebo) | rerpplopdd = zqualkvnha ohbfdvpehl (qtnzuckqra, mgszfowxsj - frsyfxhrlr) View more | ||||||
Phase 1 | 64 | (3 mg UV-4B) | navdelwkip = nzxzdmtvnh djqvnekqiy (rtgivgzlfe, qfgvoxcufe - kxyojwnbrf) View more | - | 01 Sep 2016 | ||
(10 mg UV-4B) | navdelwkip = xjuufchovh djqvnekqiy (rtgivgzlfe, tegjcagsuf - roaonwygro) View more |